[INDIANAPOLIS, USA – May 12th, 2025] – The veterinary therapeutics industry is experiencing its most radical transformation, according to a new 380-page ClearView Market Insights report. The market is projected to grow at a CAGR of 9.3% to reach $58.7 billion by 2030, driven by biomedical breakthroughs.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-veterinary-therapeutics-market/
Key Industry Shifts
- Delivery System Revolution
- KindredBio's Felpreva®:
- Weekly flea protection through a painless skin patch
- Virbac's ThyroCRON®:
- 6-month feline hyperthyroidism treatment in one chip.
- Biologic Dominance
- Elanco's mAb Therapy:
- Reduces canine itching by 89% (SCORAD scale)
- Vidium's Gene Breakthrough:
- Extends CKD cat survival by 3.2 years
- Antimicrobial Transformation
- Phage Therapy Adoption:
- Cuts dairy antibiotic use by 45% in Dutch herds
- EU Regulatory Push:
- Bans prophylactic antibiotics in 8 more species
Executive Insights
- Jeff Simmons, Elanco CEO:
"Our mAbs aren't just controlling symptoms—they're rewriting disease outcomes." - Dr. Catherine Knupp, Zoetis R&D:
"Transdermal delivery is eliminating the pill-battle for pet owners."
Clinical Impact
- Feline OA Treatment:
- Solensia® improves mobility in 82% of cases
- Dairy Productivity:
- Phage therapy increases milk yield 8% post-mastitis
Future Projections
- 2026: RNAi livestock vaccines enter commercialization.
- 2028: AI-designed polypills combine more than five chronic medications.
- 2030: 30% of medications delivered through autonomous implants
For more insights, visit https://clearviewmarketinsights.com/
About ClearView Market Insights Analytics
ClearView Market Insights Analytics is a global leader in industrial technology research, offering actionable insights across more than 100 laser market segments.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
